alexa Assessing MYC Expression in Multiple Myeloma

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Global Summit On Oncology and Breast Cancer

Vienna, Austria

Health and Medical Tourism 2020

Dubai, UAE

Global Summit on Oncology and Cancer Therapy

New York, USA
Assessing MYC Expression in Multiple Myeloma

Multiple myeloma (MM) is characterized by clonal proliferation of neoplastic plasma cells that secrete monoclonal immunoglobulin or M-protein. Prognosis in multiple myeloma is influenced not only by staging and patient factors but also by disease biology. Conventional cytogenetic studies and fluorescent in situ hybridization (FISH) are widely used currently to identify cytogenetic abnormalities and stratify MM into high risk, intermediate risk and standard risk categories. Recently, MYC gene related dysregulations, MYC over-expression and its role in prognosis has been studied in MM. MYC is a regulator gene located on chromosome 8 and it encodes for a transcription factor which plays a major role in cellular proliferation. MYC gene rearrangements in association with t (8;14), t( 8;22) and t (2;8) has been originally studied in 90% cases of Burkitt lymphoma.

Citation:

Kodali S, Yu H, Cerny J (2015) Assessing MYC Expression in Multiple Myeloma. J Hematol Thrombo Dis 3:e119. doi: 10.4172/2329-8790.1000e119

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top